Targeted drug combo shows promise for rare breast cancer subtype
NCT ID NCT04024436
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the drug futibatinib (TAS-120), alone or with the hormone therapy fulvestrant, in people with metastatic breast cancer that has specific FGFR gene changes. The study aimed to see if the treatment could shrink tumors or slow cancer growth. However, the trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Futibatinib (TAS-120) and fulvestrant
What this could lead to
If successful, this could point toward a new treatment option for people with metastatic breast cancer that has specific FGFR gene changes.
What could go wrong
This trial was terminated early, so results are limited. It is a small, early-phase study, and the drug may not work for everyone or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU Modena Policlinico
Modena, Italy
-
AOU Policlinico - Vittorio Emanuele
Catania, 95123, Italy
-
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126, Italy
-
BIDMC
Boston, Massachusetts, 02115, United States
-
Centre Leon Berard
Lyon, 69008, France
-
Centro Hospitalar Universitario Lisboa Norte
Lisbon, 1649-035, Portugal
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Florida Cancer Specialists
Fort Myers, Florida, 33901, United States
-
Florida Cancer Specialists
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists
Tallahassee, Florida, 32308, United States
-
Florida Cancer Specialists
West Palm Beach, Florida, 33401, United States
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, 00168, Italy
-
HCA Healthcare UK
London, England, W1G 6AD, United Kingdom
-
HCA Midwest Health
Kansas City, Missouri, 64132, United States
-
Institut Gustave Roussy
Villejuif, Cedex, 94805, France
-
Instituto Portugues de Oncologia do Porto
Porto, 4200-072, Portugal
-
Istituto Europeo Di Oncologia - IEO
Milan, 20141, Italy
-
Istituto Nazionale Tumori Regina Elena
Roma, 00144, Italy
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic - AZ
Phoenix, Arizona, 85054, United States
-
Mayo Clinic - FL
Jacksonville, Florida, 32224, United States
-
Mayo Clinic - MN
Rochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ospedale E. Agnelli
Pinerolo, 10064, Italy
-
Porto University
Porto, 4099-001, Portugal
-
START Madrid - CIOCC
Madrid, 28050, Spain
-
SunnyBrook Health Sciences
Toronto, M4N 3M5, Canada
-
Tennessee Oncology
Chattanooga, Tennessee, 37404, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
The Christie NHS Foundation Trust
Manchester, England, M20 4BX, United Kingdom
-
The Royal Marsden NHS Foundation Trust
Sutton, England, SM2 5PT, United Kingdom
-
Tom Baker Cancer Center
Calgary, T2N 4N2, Canada
-
USCF
San Francisco, California, 94115, United States
-
UT Southwestern
Dallas, Texas, 75390, United States
-
University Gregorio Marañon
Madrid, 28007, Spain
-
Vall d'Hebron
Barcelona, 08035, Spain